Price Alert

Magenta Therapeutics Inc. (MGTA)

NASDAQ: MGTA · Real-Time Price · USD

0.70

-0.06 (-7.69%)

At close: Sep 11, 2023, 10:00 PM

Magenta Therapeutics Statistics

Share Statistics

Magenta Therapeutics has 60.66M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	60.66M
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	33.64M
Failed to Deliver (FTD) Shares	2,075
FTD / Avg. Volume	0.84%

Short Selling Information

The latest short interest is 261.64K, so 0% of the outstanding shares have been sold short.

Short Interest	261.64K
Short % of Shares Out	n/a
Short % of Float	0.55%
Short Ratio (days to cover)	1.37

Valuation Ratios

The PE ratio is -0.03 and the forward PE ratio is null. Magenta Therapeutics's PEG ratio is 0.

PE Ratio	-0.03
Forward PE	n/a
PS Ratio	0.44
Forward PS	n/a
PB Ratio	0.01
P/FCF Ratio	-0.03
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Magenta Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.22, with a Debt / Equity ratio of 0.

Current Ratio	15.22
Quick Ratio	15.22
Debt / Equity	0
Debt / EBITDA	-0.01
Debt / FCF	-0.02
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$93.06K
Profits Per Employee	$-1.27M
Employee Count	67
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 0.06% in the last 52 weeks. The beta is 2.11, so Magenta Therapeutics's price volatility has been higher than the market average.

Beta	2.11
52-Week Price Change	0.06%
50-Day Moving Average	0.78
200-Day Moving Average	0.75
Relative Strength Index (RSI)	36.83
Average Volume (20 Days)	247,981

Income Statement

In the last 12 months, Magenta Therapeutics had revenue of 6.24M and earned -84.97M in profits. Earnings per share was -21.75.

Revenue	6.24M
Gross Profit	n/a
Operating Income	-101.86M
Net Income	-84.97M
EBITDA	-101.86M
EBIT	n/a
Earnings Per Share (EPS)	-21.75

Full Income Statement

Balance Sheet

The company has 22.79M in cash and 1.49M in debt, giving a net cash position of 21.3M.

Cash & Cash Equivalents	22.79M
Total Debt	1.49M
Net Cash	21.3M
Retained Earnings	-174.39M
Total Assets	348.58M
Working Capital	254.05M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -78.18M and capital expenditures -105K, giving a free cash flow of -78.28M.

Operating Cash Flow	-78.18M
Capital Expenditures	-105K
Free Cash Flow	-78.28M
FCF Per Share	-20.04

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1633.74%
Pretax Margin	-1362.77%
Profit Margin	-1362.77%
EBITDA Margin	-1633.74%
EBIT Margin	-1633.74%
FCF Margin	-1255.57%

Dividends & Yields

MGTA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for MGTA.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	0.24
Piotroski F-Score	3